癌治療のための再結合毒素
1Division of Cancer Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
まとめ
再結合毒素は,腫瘍細胞を特異的に標的にすることで,新しいがん治療法を提供します. 伝統的な化学療法とは異なり,これらの毒素は,異なった作用機構を提供し,交叉抵抗を回避し,二次がんのリスクを低減します.
科学分野:
- バイオテクノロジー バイオテクノロジー
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
背景:
- 従来の化学療法は,交叉抵抗性や二次悪性腫瘍などの課題に直面しています.
- 再結合毒素は,がん治療の代替治療戦略を示しています.
研究 の 目的:
- 再結合毒素の潜在能力を新しいがん治療法として探求する.
- 従来の化学療法剤に比べて再結合毒素の優位性を強調する.
主な方法:
- 成長因子-毒素,抗体-毒素融合を含む再結合毒素の開発.
- 腫瘍細胞の特定の細胞表面受容体と抗原を標的とする.
主要な成果:
- 再結合毒素は,従来の化学療法とは異なる細胞破壊メカニズムを示しています.
- これらの毒素は非変異性であり,したがって二次悪性腫瘍を誘発しません.
- バクテリアでは,均質なタンパク質の費用対効果の高い大量生産が可能である.
結論:
- 再結合毒素は,がん治療の有望で安全で潜在的により効果的なアプローチを表しています.
- 成長因子-毒素と抗体-毒素の融合の選択は,特定の細胞標的に依存します.
- このアプローチは,従来の化学療法に関連するクロスレジスタンスと遺伝子毒性の問題を回避します.
関連する概念動画
Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...


